Patients with clinically localized, high-risk cancers are at significant risk of recurrence despite local therapy. A variety of neoadjuvant strategies have been evaluated to determine the optimal approach (systemic plus local treatment) to improving outcomes in these patients.
This Research Topic will discuss current state-of-the-art management of clinically localized, high risk bladder, kidney, and prostate cancers.
For bladder cancer, neoadjuvant chemotherapy and immunotherapy will be reviewed including patient selection, dosing, side-effects and their management, and timing of local therapy.
For kidney cancer, vascular endothelial growth factor (VEGF), tyrosine kinase inhibitors (TKI) and immunotherapies will be discussed including the potential role of histology in guiding treatment.
For prostate cancer, the role of androgen deprivation therapy (ADT) in combination with radiation therapy will be summarized including choice of agents and duration of treatment. The potential role of chemotherapy in combination with ADT and radiation will be reviewed. Neoadjuvant treatment (ADT and/or chemotherapy) prior to radical prostatectomy will be addressed.
This Research Topic is to provide the most up-to-date guidance for the practitioner to manage these patients.
Patients with clinically localized, high-risk cancers are at significant risk of recurrence despite local therapy. A variety of neoadjuvant strategies have been evaluated to determine the optimal approach (systemic plus local treatment) to improving outcomes in these patients.
This Research Topic will discuss current state-of-the-art management of clinically localized, high risk bladder, kidney, and prostate cancers.
For bladder cancer, neoadjuvant chemotherapy and immunotherapy will be reviewed including patient selection, dosing, side-effects and their management, and timing of local therapy.
For kidney cancer, vascular endothelial growth factor (VEGF), tyrosine kinase inhibitors (TKI) and immunotherapies will be discussed including the potential role of histology in guiding treatment.
For prostate cancer, the role of androgen deprivation therapy (ADT) in combination with radiation therapy will be summarized including choice of agents and duration of treatment. The potential role of chemotherapy in combination with ADT and radiation will be reviewed. Neoadjuvant treatment (ADT and/or chemotherapy) prior to radical prostatectomy will be addressed.
This Research Topic is to provide the most up-to-date guidance for the practitioner to manage these patients.
